0538 GMT - News that a GSK experimental drug for chronic cough achieved negative results in late-stage studies is disappointing, but the market was cautious on the product's chances, Citi analysts say in a research note. Some saw in the drug, camlipixant, a potential candidate to help the U.K. drugmaker offset the patent expiration of its dolutegravir HIV medication, the analysts say. Still, Citi saw the drug as a high-risk asset and assigned it a 25% probability of success in its estimates, equivalent to just 1% of expected GSK revenue for 2035, they add. Similarly, consensus was cautious, with estimated 2035 sales of 750 million pounds for camlipixant accounting for 2% of group revenue, according to Citi. GSK shares closed 2% lower on Friday. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 20, 2026 01:38 ET (05:38 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.